Project 2: Specifically Targeting Oncoproteins with PCC Agent-Loaded Nanoparticles: KRASG12D and AktE17K

Pharmacology, Toxicology and Pharmaceutical Science

1. Nanoparticle 100%
2. Oncoprotein 100%
3. Monoclonal Antibody 33%
4. Epidermal Growth Factor Receptor 3 16%
5. Epidermal Growth Factor Receptor Kinase Inhibitor 16%
6. Rash 16%
7. Malignant Neoplasm 16%
8. Non Small Cell Lung Cancer 16%
9. Side Effect 16%
10. Phosphatidylinositol 3 Kinase 16%
11. Epidermal Growth Factor Receptor 16%
12. Epitope 16%
13. Combination Drug 16%
14. Therapeutic Window 16%
15. Combination Therapy 16%
16. Diseases 16%
17. Protein Kinase B 16%